至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Y06014 is a selective BET inhibitor for the treatment of prostate cancer

Acta Pharmacol Sin. 2021-03; 
Tian-Bang Wu, Qiu-Ping Xiang, Chao Wang, Chun Wu, Cheng Zhang, Mao-Feng Zhang, Zhao-Xuan Liu, Yan Zhang, Lin-Jiu Xiao, Yong Xu
Products/Services Used Details Operation
Catalog Peptides … The C-terminal biotinylated tetra-acetylated histone peptide H4 (bH4KAc4) sequence was H-SGRGK(Ac)GGK(Ac)GLGK(Ac)GGAK(Ac)RHRK-Biotin-OH (synthesized by Genscript). The experiment was conducted with protein/peptide ratio as follows for sensitive signal: BRD4(1): … Get A Quote

摘要

Bromodomain and extra-terminal proteins (BETs) are potential targets for the therapeutic treatment of prostate cancer (PC). Herein, we report the design, the synthesis, and a structure-activity relationship study of 6-(3,5-dimethylisoxazol-4-yl)benzo[cd]indol-2(1H)-one derivative as novel selective BET inhibitors. One representative compound, 19 (Y06014), bound to BRD4(1) in the low micromolar range and demonstrated high selectivity for BRD4(1) over other non-BET bromodomain-containing proteins. This molecule also potently inhibited cell growth, colony formation, and mRNA expression of AR-regulated genes in PC cell lines. Y06014 also shows stronger activity than the second-generation antiandrogen enzalutamide. ... More

关键词

BRD4, Y06014, androgen receptor, bromodomain inhibitor, prostate cancer